$-0.84 EPS Expected for Menlo Therapeutics Inc. (MNLO)

October 14, 2018 - By Marguerite Chambers

Analysts expect Menlo Therapeutics Inc. (NASDAQ:MNLO) to report $-0.84 EPS on November, 7.After having $-0.36 EPS previously, Menlo Therapeutics Inc.’s analysts see 133.33 % EPS growth. The stock increased 1.56% or $0.1 during the last trading session, reaching $6.53. About 145,296 shares traded. Menlo Therapeutics Inc. (NASDAQ:MNLO) has 0.00% since October 14, 2017 and is . It has underperformed by 15.62% the S&P500.

Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has market cap of $150.05 million. The firm has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It currently has negative earnings. It is also developing products that are in Phase II clinical trials to treat pruritus associated with psoriasis, atopic dermatitis, and refractory chronic cough.

More notable recent Menlo Therapeutics Inc. (NASDAQ:MNLO) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Affimed’s Cancer Drug Placed On Clinical Hold, Celgene’s Positive Scalp Psoriasis Trial” on October 09, 2018, also Nasdaq.com with their article: “Menlo Therapeutics Begins European Prurigo Nodularis Phase 3 Trial and Presents Additional Data from PN Phase 2 …” published on September 17, 2018, Bizjournals.com published: “Peninsula biotech coughs up 40 percent of its value on failed clinical trial” on October 08, 2018. More interesting news about Menlo Therapeutics Inc. (NASDAQ:MNLO) were released by: Nasdaq.com and their article: “Mid-Afternoon Market Update: Gold Falls 1.3%; Menlo Therapeutics Shares Plunge” published on October 08, 2018 as well as Seekingalpha.com‘s news article titled: “Menlo’s serlopitant flunks mid-stage cough study” with publication date: October 08, 2018.

Menlo Therapeutics Inc. (NASDAQ:MNLO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News